Ibrahim Turkoz
Senior Researcher, Janssen Pharmaceuticals, Inc.
Papers
8 publications
Trials
0 clinical trials
Key Impact
He is a psychiatric drug-development researcher whose work appears on multiple esketamine studies in treatment-resistant depression and suicidal ideation, contributing to the evidence base for rapid-acting antidepressant treatments.
Background & Research
Ibrahim Turkoz is a researcher at Janssen Pharmaceuticals / Janssen Research & Development in Titusville, New Jersey, where he has worked on clinical and real-world analyses in psychiatry. His publications include studies of esketamine nasal spray for treatment-resistant depression, dissociation, safety, and outcomes in acute suicidal ideation or behavior.
Collaboration Network
11 collaborators· click a node to visit their profile
Full network →